Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
49
ZVSA Quote, Financials, Valuation and Earnings
Last price:
$0.14
Seasonality move
:
-20.68%
Day range:
$0.14 - $0.14
52-week range:
$0.11 - $1.95
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.19x
Volume:
16K
Avg. volume:
35.3K
1-year change:
-88.71%
Market cap:
$1.1M
Revenue:
--
EPS (TTM):
-$5.05
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ZVSA
ZyVersa Therapeutics, Inc.
|
-- | -$2.73 | -- | -91.71% | $70.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.20 | -- | -26.67% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ZVSA
ZyVersa Therapeutics, Inc.
|
$0.14 | $70.00 | $1.1M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$5.30 | $0.85 | $667.9M | 8.90x | $0.80 | 0% | 10.30x |
|
NNVC
NanoViricides, Inc.
|
$1.24 | $6.50 | $22.3M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.88 | $2.00 | $722.3K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.4M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ZVSA
ZyVersa Therapeutics, Inc.
|
-- | 3.313 | -- | 0.04x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ZVSA
ZyVersa Therapeutics, Inc.
|
-- | -$2.1M | -711.85% | -711.85% | -- | -$1.4M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
ZyVersa Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns ZVSA or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to ZyVersa Therapeutics, Inc.'s net margin of -255.85%. ZyVersa Therapeutics, Inc.'s return on equity of -711.85% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital ZVSAZyVersa Therapeutics, Inc.-- -$2.56 -$11.7M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About ZVSA or NBY?
ZyVersa Therapeutics, Inc. has a consensus price target of $70.00, signalling upside risk potential of 14185.71%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -83.96%. Given that ZyVersa Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe ZyVersa Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ZVSAZyVersa Therapeutics, Inc.1 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is ZVSA or NBY More Risky?
ZyVersa Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock ZVSA or NBY?
ZyVersa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. ZyVersa Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZVSA or NBY?
ZyVersa Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. ZyVersa Therapeutics, Inc.'s net income of -$19.8M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, ZyVersa Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ZyVersa Therapeutics, Inc. is -- versus 10.30x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZVSAZyVersa Therapeutics, Inc.-- -- -- -$19.8M NBYNovaBay Pharmaceuticals, Inc.10.30x 8.90x $521K -$1.3M
-
Which has Higher Returns ZVSA or NNVC?
NanoViricides, Inc. has a net margin of -- compared to ZyVersa Therapeutics, Inc.'s net margin of --. ZyVersa Therapeutics, Inc.'s return on equity of -711.85% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital ZVSAZyVersa Therapeutics, Inc.-- -$2.56 -$11.7M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About ZVSA or NNVC?
ZyVersa Therapeutics, Inc. has a consensus price target of $70.00, signalling upside risk potential of 14185.71%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 424.19%. Given that ZyVersa Therapeutics, Inc. has higher upside potential than NanoViricides, Inc., analysts believe ZyVersa Therapeutics, Inc. is more attractive than NanoViricides, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ZVSAZyVersa Therapeutics, Inc.1 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is ZVSA or NNVC More Risky?
ZyVersa Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock ZVSA or NNVC?
ZyVersa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ZyVersa Therapeutics, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZVSA or NNVC?
ZyVersa Therapeutics, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. ZyVersa Therapeutics, Inc.'s net income of -$19.8M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, ZyVersa Therapeutics, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ZyVersa Therapeutics, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZVSAZyVersa Therapeutics, Inc.-- -- -- -$19.8M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns ZVSA or OGEN?
Oragenics, Inc. has a net margin of -- compared to ZyVersa Therapeutics, Inc.'s net margin of --. ZyVersa Therapeutics, Inc.'s return on equity of -711.85% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital ZVSAZyVersa Therapeutics, Inc.-- -$2.56 -$11.7M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About ZVSA or OGEN?
ZyVersa Therapeutics, Inc. has a consensus price target of $70.00, signalling upside risk potential of 14185.71%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 127.84%. Given that ZyVersa Therapeutics, Inc. has higher upside potential than Oragenics, Inc., analysts believe ZyVersa Therapeutics, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ZVSAZyVersa Therapeutics, Inc.1 0 0 OGENOragenics, Inc.1 0 0 -
Is ZVSA or OGEN More Risky?
ZyVersa Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock ZVSA or OGEN?
ZyVersa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ZyVersa Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZVSA or OGEN?
ZyVersa Therapeutics, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. ZyVersa Therapeutics, Inc.'s net income of -$19.8M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, ZyVersa Therapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ZyVersa Therapeutics, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZVSAZyVersa Therapeutics, Inc.-- -- -- -$19.8M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns ZVSA or PTN?
Palatin Technologies has a net margin of -- compared to ZyVersa Therapeutics, Inc.'s net margin of --. ZyVersa Therapeutics, Inc.'s return on equity of -711.85% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ZVSAZyVersa Therapeutics, Inc.-- -$2.56 -$11.7M PTNPalatin Technologies-- -- -- -
What do Analysts Say About ZVSA or PTN?
ZyVersa Therapeutics, Inc. has a consensus price target of $70.00, signalling upside risk potential of 14185.71%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that ZyVersa Therapeutics, Inc. has higher upside potential than Palatin Technologies, analysts believe ZyVersa Therapeutics, Inc. is more attractive than Palatin Technologies.
Company Buy Ratings Hold Ratings Sell Ratings ZVSAZyVersa Therapeutics, Inc.1 0 0 PTNPalatin Technologies0 0 0 -
Is ZVSA or PTN More Risky?
ZyVersa Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock ZVSA or PTN?
ZyVersa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ZyVersa Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZVSA or PTN?
ZyVersa Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. ZyVersa Therapeutics, Inc.'s net income of -$19.8M is higher than Palatin Technologies's net income of --. Notably, ZyVersa Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ZyVersa Therapeutics, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZVSAZyVersa Therapeutics, Inc.-- -- -- -$19.8M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns ZVSA or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to ZyVersa Therapeutics, Inc.'s net margin of --. ZyVersa Therapeutics, Inc.'s return on equity of -711.85% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital ZVSAZyVersa Therapeutics, Inc.-- -$2.56 -$11.7M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About ZVSA or TOVX?
ZyVersa Therapeutics, Inc. has a consensus price target of $70.00, signalling upside risk potential of 14185.71%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3570.69%. Given that ZyVersa Therapeutics, Inc. has higher upside potential than Theriva Biologics, Inc., analysts believe ZyVersa Therapeutics, Inc. is more attractive than Theriva Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ZVSAZyVersa Therapeutics, Inc.1 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is ZVSA or TOVX More Risky?
ZyVersa Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock ZVSA or TOVX?
ZyVersa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ZyVersa Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZVSA or TOVX?
ZyVersa Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. ZyVersa Therapeutics, Inc.'s net income of -$19.8M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, ZyVersa Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ZyVersa Therapeutics, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZVSAZyVersa Therapeutics, Inc.-- -- -- -$19.8M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
